Literature DB >> 15721837

Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1.

Devki Nandan1, Neil E Reiner.   

Abstract

Protozoan parasites of the genus leishmania are obligate intracellular parasites of monocytes and macrophages. These pathogens have evolved to invade the mammalian immune system and typically survive for long periods of time. Leishmania have developed a variety of remarkable strategies to prevent their elimination by both innate and acquired immune effector mechanisms. One particular strategy of interest involves manipulation of host cell regulatory pathways so as to prevent macrophage activation required for efficient microbicidal activity. These interference mechanisms are the main focus of this review. Several lines of evidence have been developed to show that the Src homology-2 domain containing tyrosine phosphatase-1 (SHP-1) becomes activated in leishmania-infected cells and that this contributes to disease pathogenesis. Recent studies aimed at understanding the mechanism responsible for the change in activation state of SHP-1 led to the identification of leishmania EF-1alpha as an SHP-1 binding protein and SHP-1 activator. This was a surprising finding given that this ubiquitous and highly conserved protein plays an essential role in protein translation in both prokaryotic and eukaryotic cells. The role of leishmania EF-1alpha as an SHP-1 activator and its contribution to pathogenesis are reviewed with particular attention to the properties that distinguish it from host EF-1alpha.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721837     DOI: 10.1016/j.clim.2004.07.017

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  36 in total

Review 1.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

Review 2.  Shp1 function in myeloid cells.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

3.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

4.  Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Prosenjit Sen; Suniti Bhaumik; Pradip Sen; Subha Banerjee; Ksudiram Naskar; Soumitra K Choudhuri; Bhaskar Saha; Sanghamitra Raha; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.

Authors:  Thomas Bakken; Meilan He; Mark L Cannon
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

6.  Leishmania major abrogates gamma interferon-induced gene expression in human macrophages from a global perspective.

Authors:  Nisha Dogra; Corinna Warburton; W Robert McMaster
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

Review 7.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15

Review 8.  Leishmania interferes with host cell signaling to devise a survival strategy.

Authors:  Suvercha Bhardwaj; Neetu Srivastava; Raki Sudan; Bhaskar Saha
Journal:  J Biomed Biotechnol       Date:  2010-04-08

9.  Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Authors:  Manu Vanaerschot; Ilse Maes; Meriem Ouakad; Vanessa Adaui; Louis Maes; Simonne De Doncker; Suman Rijal; François Chappuis; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

10.  Identification of Leishmania proteins preferentially released in infected cells using change mediated antigen technology (CMAT).

Authors:  Peter E Kima; J Alfredo Bonilla; Eumin Cho; Blaise Ndjamen; Johnathan Canton; Nicole Leal; Martin Handfield
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.